Compugen (CGEN) Stifel 2026 Targeted Oncology Virtual Forum summary

Company overview and platform

• Pioneering AI-based computational discovery for immuno-oncology drug targets, validated through repeated identification of novel targets and pharma collaborations.

• Internal assets and partnerships with major pharma companies like Gilead and AstraZeneca stem from this platform.

COM701 clinical development

• COM701, a PVRIG checkpoint inhibitor, targets platinum-sensitive ovarian cancer in a randomized, placebo-controlled trial (MAIA) with a key readout in Q1 2027.

• Patient selection focuses on earlier-line, platinum-sensitive cases without liver metastasis to maximize response rates.

• The trial randomizes 40 patients to COM701 and 20 to placebo, with progression-free survival as the primary endpoint.

• Interim futility analysis is planned for early 2025, with potential for adaptive expansion into combinations or other indications.

• Addressable market for initial indication estimated at 8,000–12,000 patients, expandable to ~30,000 with broader combinations.

Gilead partnership (GS-0321)

• GS-0321, a first-in-class antibody harnessing cytokine biology, is in phase I dose escalation for solid tumors.

• Compugen leads the phase I trial, with Gilead taking over for phase II and beyond; collaboration is described as close and productive.

• $90 million received to date, with up to $758 million in future milestones and low double-digit royalties possible.